Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Issue Optimal Use Guidelines for Dupixent, Tecentriq
April 12, 2018
- MHLW Panel Starts Discussions on PMD Law Amendment; Will First Verify Results of Previous Amendment
April 12, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
- Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
- MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs
April 12, 2018
- Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
- Doctor Calls for Incentives for Effective, Lower-Cost Existing Drugs: LDP Taskforce
April 10, 2018
- MHLW Inks Memorandum of Cooperation with FDA Thailand
April 10, 2018
- MHLW to Launch New Public-Private Confab Focusing on Drug Pricing
April 10, 2018
- Mandatory Generic Use Tantamount to Treating Welfare Recipients in “Inferior” Manner: Lawmaker
April 6, 2018
- MEXT to Support Establishment of “Open Innovation Organizations” at Universities
April 6, 2018
- Invest in DNA-Based Prevention for Cancer, Dementia and Other Technological Innovation: CEFP Member
April 5, 2018
- MHLW Panel to Kick Off Debates on Amendment of Pharmaceuticals and Medical Devices Law
April 5, 2018
- PMDA Announces Report Outlining “Current Views” on Introduction of Continuous Manufacturing
April 5, 2018
- Ono Takes over Orphan Designation for 2 Products Including MEK Inhibitor from Array BioPharma
April 4, 2018
- MHLW to Discuss Stockpiling of Xofluza, Tamiflu Generics in FY2018
April 3, 2018
- Use of Big Data Entering New Stage with Launch of MID-NET, Enforcement of New Law
April 3, 2018
- AMED Out-Licenses 2 Compounds in Drug Discovery Support Initiative
April 2, 2018
- Chuikyo Begins Debate on Sales Tax Hike, Agrees on Drug Price Survey in 2018
April 2, 2018
- MHLW Orders Package Insert Revisions for Antibacterial Drugs
March 29, 2018
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…